Year-end Sale % OFF 
Abstract
Expression of ZFAS1, a newly identified long noncoding RNA (lncRNA), is dysregulated in several types of cancer. Here we assessed the prognostic value of ZFAS1 in solid tumors. A comprehensive literature search was performed by screening the PubMed, EMBASE, MEDLINE, Cochrane Library, CNKI, and Wanfang databases. A total of 874 patients from 10 studies were included. The pooled analysis demonstrated that patients with high ZFAS1 expression had a significantly shorter overall survival (OS) (HR, 1.58; 95% CI, 1.28–1.97; P < 0.001) and recurrence-free survival (RFS) (HR, 1.90; 95% CI, 1.29–2.79; P = 0.001). Moreover, elevated ZFAS1 expression correlated with tumor size, tumor-node-metastasis (TNM) stage, and lymph node metastasis (LNM). These results demonstrate that increased ZFAS1 expression correlates with a poor prognosis in cancer patients, which suggests ZFAS1 might be useful as a potential prognostic biomarker in patients with solid tumors.
Highlights
Cancer is a major cause of morbidity and mortality worldwide [1, 2]
Various cancers were recorded in our study, including hepatocellular carcinoma (HCC), gastric cancer (GC), colorectal cancer (CRC), non-small cell lung cancer (NSCLC), ovarian cancer (OC), colonic cancer (CC), and glioma
Increased Zinc finger antisense 1 (ZFAS1) expression has been associated with malignant progression, metastasis, and poor prognosis in several types of cancer [31,32,33]
Summary
Cancer is a major cause of morbidity and mortality worldwide [1, 2]. Despite significant advances in medical care, the prognosis of cancer is still extremely poor. It is vital to develop specific and sensitive biomarkers for early diagnosis and more accurate cancer prognosis. Despite the outdated opinion that lncRNAs represent a transcriptional noise [4], emerging evidence suggests that lncRNAs play a pivotal role in the development and progression of cancer [5, 6]. LncRNAs have been recogn ized as hallmarks of the onset and development of various types of cancer [9,10,11,12]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
